Host: |
Mouse |
Applications: |
WB/IHC/IF/ELISA |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Mouse monoclonal antibody anti-Calcyclin-binding protein is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications. |
Clonality: |
Monoclonal |
Clone ID: |
7D11 |
Conjugation: |
Unconjugated |
Isotype: |
IgG1 |
Formulation: |
Liquid in PBS containing 0.03% Sodium Azide. |
Purification: |
Affinity purification |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-1:2000IHC 1:200-1:1000ELISA 1:10000IF 1:50-200 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CACYBP |
Gene ID: |
27101 |
Uniprot ID: |
CYBP_HUMAN |
Specificity: |
Calcyclin Monoclonal Antibody detects endogenous levels of Calcyclin protein. |
Immunogen: |
Purified recombinant fragment of Calcyclin expressed in E. Coli. |
Function | May be involved in calcium-dependent ubiquitination and subsequent proteasomal degradation of target proteins. Probably serves as a molecular bridge in ubiquitin E3 complexes. Participates in the ubiquitin-mediated degradation of beta-catenin (CTNNB1). |
Protein Name | Calcyclin-Binding ProteinCacybpHcacybpS100a6-Binding ProteinSiah-Interacting Protein |
Cellular Localisation | NucleusCytoplasmCytoplasmic At Low Calcium ConcentrationsIn Neuroblastoma CellsAfter A Retinoic Acid (Ra) Induction And Calcium IncreaseIt Localizes In Both The Nucleus And CytoplasmThe Nuclear Fraction May Be Phosphorylated |
Alternative Antibody Names | Anti-Calcyclin-Binding Protein antibodyAnti-Cacybp antibodyAnti-Hcacybp antibodyAnti-S100a6-Binding Protein antibodyAnti-Siah-Interacting Protein antibodyAnti-CACYBP antibodyAnti-S100A6BP antibodyAnti-SIP antibodyAnti-PNAS-107 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance